• New capabilities to be launched on March 25
  • Unique technology bolsters BullFrog AI’s end-to-end AI intelligence workflow with a scenario-based decision engine
  • Advances current AI decision tools by clearly defining clinical trial strategies and building diversified, risk-balanced R&D portfolios

GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design.

The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision layer on top of existing platforms bfPREP™ and bfLEAP ® . Unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings, the upcoming offering evaluates options using proprietary algorithms and methodologies revealing which programs are robust winners and which succeed only under narrow conditions.

Key capabilities include:

  • Compares drug programs, indications, and trial designs without forcing arbitrary numerical scores
  • Tests portfolio decisions against multiple explicit scenarios (e.g., capital-constrained, platform-building, US-first, global)
  • Identifies options that perform well across strategic futures
  • Preserves portfolio diversity while surfacing clear leaders to balance concentration with risk mitigation

“Each year, more than $200 billion is spent by life science and pharmaceutical companies on research and development, with very low returns given an estimated 90% clinical trial failure rate. While AI adoption in drug discovery has accelerated, strategic portfolio decisions still rely largely on manual scoring and spreadsheet-based tools that force rigid rankings on fundamentally comparative judgments,” said BullFrog AI Founder and CEO Vin Singh. “Our new capability takes a different approach by treating strategic scenarios as first-class inputs. It surfaces robust recommendations and highlights options that perform well under multiple strategic futures—enabling clear R&D strategies and the construction of diversified, risk-balanced R&D portfolios. To our knowledge, no other solution in the world can offer this capability.”

Please visit the BullFrog AI website for updates on the new product launch.

About BullFrog AI

BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP ® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com .

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors:
CORE IR
[email protected]

Media:
CORE PR
[email protected]